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Low molecular weight heparin in hemodialysis and hemoffitration
patients. Low molecular weight (LMW)-heparin was used as the sole
anticoagulant during hemodialysis and hemofiltration in a pilot study on
32 patients. A LMW-heparin dose corresponding to 50% of the patients
usual unfractionated, standard (UF)-heparin dose was found to produce
comparable plasma heparin levels (anti-FXa-activity). No thrombosis
of the extracorporal system and no bleeding complications occurred at
this LMW-heparin dose. In contrast to UF-heparin, LMW-heparin
produced only slight increases in PTT and thrombin time in all patients.
Lipoprotein lipase was stimulated only marginally by LMW-heparin,
with a correspondingly reduced release of free fatty acids. Both heparin
species caused similar elevations in factor VIII and fibrin monomers,
thus excluding a difference in coagulation activation. On the basis of
these results, long-term studies have been started at four nephrology
centers. To date, 26 patients have been treated with LMW-heparin for
6 months. A LMW-heparin dose was used that produced plasma
anti-FXa-activity of 0.5 to 0.9 U/ml (initial dose: 30 to 40; dose/hr: 8 to
15 anti-FXa-units/kg body wt). PTI' and thrombin time were only
increased by 5 sec on average. Surprisingly, the elevated pre-dialysis
levels of factor VIII and fibrin monomers decreased during this 6-month
period. Bleeding complications did not occur and thrombotic compli-
cations were not observed when the anti-FXa levels were above 0.5
U/mi. LMW-heparin, therefore, appears to be a good alternative to
UF-heparin for dialysis patients and may present less risk of bleeding
because of its reduced effect on PTT, thrombin time, and thrombocytes.
Héparine de faible poids moléculaire chez des malades hemodialysés et
hémoflitrés. Une héparine de faible poids moléculaire (LMW) a été
utilisée comme unique anticoagulant au cours de l'hémodialyse et de
l'hémofiltration dans une étude pilote chez 32 malades. Une dose
d'héparine LMW correspondant a 50% de Ia dose standard d'héparmne
(UF) habituelle non fractionnée des malades, s'est avérée produire des
niveaux comparables d'héparmnémie (activité anti-FXa). Aucune
thrombose du système extra corporel, ni aucune complication
hémorragique ne s'est produite avec cette dose de LMW-héparine. A
l'opposé de l'héparine UF, l'héparine LMW entrainait simplement des
augmentations modérées de PTF et du temps de thrombine chez tous
les malades. La lipoprotéine lipase n'était que stimulée de facon
marginale par l'héparine LMW, avec un relargage réduit correspondant
des acides gras libres. Les deux types d'héparine entrainaient des
élévations identiques du facteur VIII et des monomères a la fibrine,
excluant ainsi une difference de l'activation de Ia coagulation. Sur la
base de ces résultats, des etudes a long terme ont etC démarrCes dans
quatre centres de nephrologie, A cc jour, 26 malades ont etC traités avec
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de l'hCparine LMW pendant 6 mois. La dose d'hCparine LMW utilisCe
Ctait celle produisant une activité anti-FXa plasmatique de 0,5 a 0,9
U/ml (dose initiaie: 30 a 40; dose/hr: 8 a 15 unites anti-FXa/kg poids),
PTI' et le temps de thrombine n'étaient que modCrément augmentCs de
5 sec en moyenne. Dc facon inattendue, les niveaux predialytiques
élevCs de facteur VIII et de monoméres de la fibrine ont diminuC au
cours de cette pCriode de 6 mois. Des complications hemorragiques ne
se sont pas produites, et des complications thrombotiques n'ont pas etC
observCes tant que les niveaux d'anti-FXa Ctaient supCrieurs a 0,5
U/ml. L'hCparine LMW semble done une bonne alternative a l'hCparine
UF chez les hémodialysCs, et pourrait presenter moms de risques
hCmorragiques en raison de son effet rCduit sur PTT, Ic temps de
thrombine, et les thrombocytes.
Heparin preparations presently in use in clinics and dialysis
units are heterogenous mixtures of linear anionic polyelectro-
lytes of differing chain lengths. Their molecular weights gener-
ally range from 5,000 to 30,000, the average being about 12,000
to 15,000 [1—4]. Investigations with heparin fractions of different
molecular weights have demonstrated a correlation between
molecular weight and anticoagulant activity. With decreasing
molecular weight there is an increase in factor Xa inhibition and
a reduction in thrombin inhibition. Thus, fractionated low
molecular weight (LMW) heparin has a high affinity for anti-
thrombin III and strongly inhibits factor Xa, FXIIa and kal-
likrein, but only weakly inhibits thrombin and factors IX and
XI. In contrast to normal unfractionated (UF) heparin, LMW-
heparin causes only a slight increase in PTT and thrombin time
[1-6].
Since the anti-thrombotic effectiveness of heparin is related
to its anti-FXa-activity, whereas increased bleeding risk is
associated with an increase in PTT, it might be expected that
the use of LMW-heparin will reduce bleeding risk in patients
while maintaining anti-thrombotic activity [1, 3—5, 7—13].
In this study we have compared the use of LMW-heparin
with UF-heparin in patients on hemodialysis and hemofiltra-
tion. In an initial short-term pilot study, the LMW-heparin dose
necessary for effective anti-coagulation was first ascertained.
After this dose had been established, a long-term, multi-center
study was started: 26 patients with chronic end-stage renal
failure are being chronically treated with LMW-heparin in four
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Table 1. Mean values for UF-heparin and LMW-heparin doses in 14
patients at bleeding risk and in 18 patients without recognizable
bleeding risk
Doses
UF-Heparin
lu/kg
LMW-Heparin
Anti-Xa-U/kg
Bleeding risk Initial dose 26.2 6.8 13.1 3.4
patients Dose/hr 11.8 1.8 5.9 0.9(N = 14)
No bleeding risk Initial dose 40.2 8.8 20.1 4.4
patients Dose/hr 20.6 3.6 10.3 1.8(N = 18)
different dialysis centers. We now present the results from the
first 6 months of treatment.
Methods
Initial pilot study
The anti-coagulant efficiency of a LMW-heparin dose equiv-
alent to one-half of the UF-heparin dose that the patients
normally received was tested in 32 patients (20 female, 12 male)
being treated for renal insufficiency by hemodialysis (20 pa-
tients) or hemofiltration (12 patients). The units of UF-heparin
are expressed as international units (IU) while those of LMW-
heparin are expressed as anti-FXa-units. For the sake of
convenience we refer to the LMW-heparin and UF-heparin
doses as being equivalent when they contain the same number
of anti-FXa-units and international units, respectively.
Fourteen patients were receiving a minimal heparin dose
because of high bleeding risk, while the remaining 18, who were
not at risk, were receiving a higher dose. Mean values and
standard deviations for the initial bolus and the continuous
infusion are presented in Table 1.
Twenty-six patients were suffering from chronic terminal
renal insufficiency and six from acute renal insufficiency.
Long-term study
In a second study, the chronic use of LMW-heparin was
investigated in an additional 26 patients with chronic end-stage
renal failure who are being treated at four different nephrology
centers. Twenty patients are on hemodialysis, six on hemofil-
tration; 15 are female and 11 male, Time on dialysis prior to this
study varied between 5 and 47 months. The results of the first 6
months of treatment have been evaluated in the present article.
Blood sampling
Blood samples were taken at the beginning of each hemofil-
tration or hemodialysis treatment and after 2 hrs of treatment.
In the pilot study, a 4-hr sample was also taken. The samples
were drawn immediately after the blood had entered the
extracorporal system and before the point at which heparin was
injected. Single samples were collected and the assays were
performed in duplicate. In the long-term study, samples were
taken on the first day of treatment with LMW-heparin and then
after an additional 2, 4, 8, 16, and 24 weeks of treatment.
Analytical procedures
The following parameters were determined: heparin as anti-
FXa-activity (chromogenic substrate S-2222; Kabi Vitrum,
Munich, Federal Republic of Germany), APTT (Pathromtin;
Behring, Marburg, Federal Republic of Germany), thrombin
time (Roche, Grenzach, Federal Republic of Germany),
thromboplastin time according to Quick (Ca-Thromboplastin,
Behring, Marburg), fibrinogen according to Clauss (Immuno,
Heidelberg, Federal Republic of Germany), fibrin monomers
(protamine sulfate test) [14], F VIII activity (Behring), anti-
thrombin III activity (chromogenic substrate S-2238; Kabi),
hematocrit, total lipase, and lipoprotein lipase [15, 16], free
fatty acids [17], plasminogen and cs2-antiplasmin (chromogenic
substrate S-225l) [18], thrombocytes, urea, and creatinine.
Dialysis/filtration procedure
During all studies, the particular dialysis/filtration procedure
used for each patient was not altered; the same type of dialyzer
or hemofilter was always used in the same patient. Each
dialysis/filtration lasted between 4'/2 and 5 hrs. The blood flow
rate was between 150 and 350 mI/mm. Antithrombotic effec-
tiveness was judged macroscopically (no clot in the extracor-
poral circulation or no fibrin in the dialyzers or filters) and from
laboratory results (no significant increase in fibrin monomers as
compared to UF-heparin).
Heparin preparations
The LMW-hepann preparation Kabi 2165 (Kabi Vitrum,
Sweden) was used in these investigations.
LMW-heparin Kabi 2165: Average molecular weight: 4,000
to 5,000 daltons, anti-FXa-activity (chromogenic substrate S-
2222): 160 U/mg; APTT: 40 lU/mg, anti-FXaJAPTT-ratio = 4.
UF-heparin Braun (Melsungen): Average molecular weight:
12,000 to 15,000, anti-FXa-activity (chromogenic substrate
S-2222): 175 U/mg; APTT:165 lU/mg, anti-FXaJAPTT-ratio
1.
Statistics
Variance analysis was applied to the results from the pilot
study. Differences were considered to be significant for P <
0.001.
Results
Initial pilot study
Thirty-two patients received a LMW-heparin dose corre-
sponding to one-half of their usual UF-hepann dose. In those
patients at bleeding risk on minimal heparinization, the LMW-
heparin dose produced plasma heparin levels similar to those
obtained with UF-heparin (between 0.45 to 0.50 anti-FXa-U).
In the remaining patients on a higher LMW- and UF-heparin
dose, significantly higher plasma-heparin levels were obtained
with UF-heparin (0.76 to 0.83) as compared to LMW-heparin
(0.54 to 0.62) (Fig. 1).
There was no evidence of thrombosis formation in the
extracorporal circulation of any of these 32 patients, whether
they received UF- or LMW-heparin.
Highly significant differences were observed in PTT (Fig. 2)
and thrombin time (Fig. 3) between UF- and LMW-heparin at
both low and high doses. On low doses, PTT rose by 50 to 80
sec with UF-heparin, but only by 3 to 5 sec with LMW-heparin,
while the corresponding values at the higher doses were 140 to
160 sec for UF-heparin and 8 to 10 sec for LMW-heparin.
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Thrombin time increased by 80 to 130 sec at low doses and by
260 to 290 sec at higher doses with UF-heparin. The corre-
sponding increases with LMW-heparin were 2 to 3 and 6 to 7
sec, respectively.
For the laboratory control of therapy with UF- and LMW-
heparin, it is important to consider the correlation between
plasma heparin levels and both PU and thrombin time. A good
positive correlation was observed between both PU and
thrombin time and the plasma heparin level using UF-heparin
(Table 2), but not using LMW-heparin.
Table 3 summarizes the results obtained for the other param-
eters that were monitored in this study. They have been
evaluated for all 32 patients since no significant differences were
observed between those patients on the low heparin dose and
those on a high dose. A slight increase in fibrin monomers had
occurred after 2 hrs of treatment using LMW-heparin. This
difference was not however significant (P 0.04). After 4 hrs,
the mean values under both UF- and LMW-heparin were
slightly higher than the values at the beginning of dialysis.
There was, however, no significant difference between UF- and
LMW-heparin. F VIII activity increased by an average of 60 to
80% during dialysis, there being no significant differences
between the two heparins. No changes were observed in
fibrinogen, antithrombin III, plasminogen, a2-antiplasmin, or
thromboplastin time according to Quick and hematocrit. Total
lipase, lipoprotein lipase, and free fatty acids were measured in
six patients (all with chronic renal insufficiency), three on the
minimal heparin dose and three on the higher dose. Total lipase
activity, lipoprotein lipase activity, and free fatty acids were
significantly higher under UF-heparin as compared to LMW-
heparin.
Long-term study
In a long-term multi-center study, a total of 26 patients have
now been treated for 6 months with LMW-heparin. Plasma
heparin levels 2 hrs after the start of dialysis were monitored
over this period and are presented in Figure 4. Thrombotic
material was found in the dialyzer of five patients during the
first week and again in two of these patients during the second
week of treatment. In these cases plasma anti-FXa-activity was
found to be between 0.2 to 0.4 UIml. After increasing the
LMW-heparin dose, no further thrombotic material was ob-
served. The results suggest that the LMW-heparin dose should
be sufficient to produce plasma anti-FXa-levels of at least 0.5
anti-FXa U/ml to avoid thrombosis formation in the dialyzer.
Both PTT and thrombin time were only marginally elevated by
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Fig. 1. Plasma heparin levels as determined by anti Xa activity with UF-
or LMW-heparin in 14 patients at bleeding risk and in 18 patients
without recognizable bleeding risk. The LMW-heparin dose was 50% of
the usual UF-heparin dose (* = P < 0.001).
UF LMW UF LMW UF LMW
Before 2hr after 4hr after
Start of dialysis
Fig. 2. PIT in 14 patients at bleeding risk and in 18 patients without
recognizable bleeding risk under either UF- or LMW-heparin. The
LMW-heparin dose was 50% of the usual UF-heparin dose (* = P <
0.001).
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Fig. 3. Thrombin time in 14 patients at bleeding risk and in 18 patients
without recognizable bleeding risk under either UF- or LMW-heparin.
The LMW-heparin dose was 50% of the usual UF-heparin dose (* = P
<0.001).
Table 2. Correlation coefficients (CC) between plasma hepann levels,
PTT, and thrombin time on UF- and LMW-heparin therapy (N = 96)
CC UF-heparin LMW-heparin
PTT-heparin 0.89 0.53
Thrombin time hepann 0.84 0.61
an average of 5 sec after administration of LMW-hepann (Fig.
5).
Surprisingly, a decrease in the factor VIII activity measured
prior to dialysis was observed over the 6-month period, even
though dialysis itself led to a slight increase in this activity.
Predialysis values for fibrin monomers also decreased during
the first 2 weeks of treatment, and then remained relatively
stable (Fig. 6). No significant changes were observed in anti-
thrombin III, thromboplastin time, fibrinogen, a2-anti-plasmin
and plasminogen, hemoglobin, leucocytes, thrombocytes, cre-
atinine, urea, GPT, GOT, cholesterol, and triglycerides.
Discussion
Animal experiments have shown that heparin fractions of
decreasing molecular weight have increased anti-FXa-activity
and greater antithrombotic effectiveness [4, 5, 19]. A minimal
molecular weight appears to be necessary, below which
antithrombotic activity diminishes rapidly [4, 6, 20]. Thus, a
heparin fragment with a molecular weight of 2,100 showed only
slight antithrombotic activity [4]. Heparin fragments with an
average molecular weight of 4,000 to 5,000, such as the LMW-
heparin preparation, Kabi 2165, which was used in the present
investigation, are of optimal size with regard to antithrombotic
effectiveness and high anti-FXa-activity. At the same time, they
only have a slight effect on PTT and thrombin time [3, 4, 61.
These last two properties are of particular importance since
increased PTT and thrombin time are generally regarded as
parameters for the effectiveness of anticoagulation and, as
such, are indicative of higher bleeding risk [3, 8, 10—12, 21—23].
It might, therefore, be expected that the use of LMW-heparin
will reduce bleeding risk while still maintaining anti-thrombotic
activity. Indeed, it could be shown in animal experiments that
this is the case [8, 19]. In addition to the marginal effects on PTT
and thrombin time, LMW-heparin has no effect on
thrombocytes and fibrinolysis. This should also lead to a
reduced bleeding risk compared to UF-heparin [6, 8, 19, 24, 251.
In patients with heparin-induced thrombopenia, LMW-heparin
appears to be a useful therapeutic alternative [26].
The present investigations were undertaken to determine the
therapeutically effective dose of LMW-heparin in patients being
treated for renal failure by hemodialysis and hemofiltration to
confirm the potentially favorable properties of LMW-heparin.
In initial studies on 32 patients, it was found that a LMW-
heparin dose equivalent to one-half of the patients usual UF-
heparin dose produced the same plasma-heparin levels as the
UF-heparin dose. No thrombosis formation, visible fibrin clots,
or bleeding complications were observed in these 32 patients.
The plasma-heparin levels under both UF- and LMW-heparin
were similar, even in the 14 patients at high bleeding risk who
were on a minimal heparin therapy. According to our present
experience with LMW-heparin, we would suggest an initial
dose of 7 to 10 anti-FXa-U/kg, followed by a continuous
infusion of about 5 anti-FXalkg!hr in the treatment by dialysis of
patients at bleeding risk. The anti-FXa-levels should then be
between 0.2 to 0.3 to (0.4) anti-FXa-U/ml [12]. In the remaining
18 patients not at bleeding risk who received higher heparin
doses, UF-heparin produced a higher plasma-heparin level than
LMW-heparin. This may possibly be due to a difference in the
clearance rates of the two heparin species because their dif-
ferent molecular weights lead to a different affinity for heparin
degrading enzymes. Whether or not this is suggestive of a
greater therapeutic range for LMW-heparin will require further
investigation. For patients without a recognizable bleeding risk,
LMW-heparin doses of about 30 to 40 U/kg as initial dose and
an infusion of 10 to 15 U/kg/hr can be applied. Plasma heparin
levels should then be 0.5 anti-FXa U/mi or greater [12, 27].
In contrast to UF-heparin, LMW-heparin caused only a slight
increase in both PTT and thrombin time in these patients. This
is in agreement with other observations [3, 5, 6, 9, 13] that an
effective anti-thrombotic activity can be achieved even when
PU and thrombin time are increased only marginally. Thus
anti-thrombotic effectiveness is not necessarily related to
anticoagulant activity as expressed by PU and thrombin time.
This would suggest that for the laboratory control of therapy
with LMW-heparin, only the one coagulation parameter need
be measured, namely, the anti-FXa-activity [28].
Both UF- and LMW-heparin caused similar changes in both
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Table 3. Mean values and standard deviations for coagulation and fibrinolysis parameters (N = 32), hematocrit (N = 32), total lipase,
lipoprotein lipase, and free fatty acids (N = 6)
Before start of dialysis 2 hr after start of dialysis 4 hr after Start of dialysis
UF LMW UF LMW UF LMW
Factor VIII, % 187 191 264 280 273 272
Fibrin monomers, % 0.32
0.12
0.28
0.15
0.27
0.16
0.59
0.30
0.43
0.18
0.54
0.24
Fibrinogen, mg% 293 303 315 320 333 340
Thromboplastin time, % 89 84 84 79 83 80
Antithrombin III, % 95 101 102 107 106 111
Plasminogen, % 105
19
105
14
110
20
112
16
113
17
117
20
a2-Antiplasmin, % 108 106 114 115 116 117
Hematocrit, % 26.6
4.1
26.5
4.4
28.4
6.1
27.1
5.6
28.2
5.8
27.8
5.9
Lipoproteinlipase, mole/ml/hr 8.16
2.28
2.49*
0.75
Total lipase, .tmoleIml/hr 18.73
4.08
6.03*
1.69
Free fatty acids, mg% 11.8
4.4
7.5
2.3
61.6
26.4
26.9*
15.1
Symbol: %, percentage of a normal standard plasma pool. In the case of fibrin monomers and hematocrit, % represents volume percentage.
* P < 0.001, N = 6.
x
C
Plasma heparin levels
(N = 26)
F-VIII-activity and fibrin monomers so that a difference in
coagulation activation between the two hepann species can be
excluded. Since there were no alterations in thromboplastin
time, fibrinogen, antithrombin III, plasminogen and a2-anti-
plasmin even on minimal heparin therapy, there would appear
to be no major changes in the coagulation and fibrinolytic
systems on LMW-heparin therapy.
In contrast to UF-heparin, LMW-heparin caused only a slight
activation of lipoprotein lipase resulting in reduced release of
free fatty acids [11, 12, 29].
The clinical importance of the reduced stimulation of lipopro-
tein lipase activity lies in the effect of lipoprotein lipase and free
fatty acids on atherosclerosis development, platelets, and the
displacement of protein-bound drugs (29—35).
The effectiveness of LMW-heparin was confirmed by the first
results from a long-term study on dialysis patients. Surpris-
ingly, predialysis plasma factor VIII activity, and fibrin mono-
mer levels decreased during the study period of 6 months. It is
often reported that patients with chronic end-stage renal failure
have elevated fibrin monomers and factor VIII activity, indi-
cating hypercoagulability. This may be of importance in the
development of vascular events (11, 36—40). It should be noted
that these patients had been on dialysis treatment for a longer
duration prior to this study without any alterations in factor VII
activity and fibrin monomer levels being noted. As yet, there is
no explanation for this decrease. It can be speculated that there
is a greater binding of LMW-hepann to the vascular endothe-
lium or that diminished alterations of lipid metabolism or
thrombocytes might lead to reduced effects on the coagulation
system.
In conclusion, LMW-heparin would appear to be a suitable
alternative to UF-heparin for the treatment of renal insuffi-
Initial dose 24.3 8.6 28.5 8.2 30.3 7.5 31.2 7.8 30.5 7.2 30.5 7.2 Anti-FXa
Dose/hr 9.8 2.2 10.6 2.6 10.9 2.2 11.2 2.3 11.5 2.5 11.5 2.5 U/kg
0.8
0.6
0.4
0.2
1 day 2wk —1— —2— —4— 6 months
Fig. 4. Plasma heparin levels as determined by
anti Xa activity in 26 hemodialysis patients
during 6 months on LMW-heparin. Symbols
are: , before dialysis; iii, 2 hrs after start of
dialysis.
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PiT
(N = 26)Sec
Sec
Thrombin time
(N = 26)
1 day 2 wk —1— —2— —4— 6 months
Fig. 5. PTT and thrombin time in 26 hemodialysis patients during 6
months on LMW-heparin. Symbols same as Fig, 4.
ciency by dialysis. Furthermore, this heparin preparation may
prove to have several advantages over normal UF-heparin
because of its reduced bleeding risk and its marginal influence
on PTT, thrombin time, thrombocytes, and lipoprotein lipase.
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